Isodiol International Inc. (CSE:ISOL) (OTCQB:ISOLD) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global CBD innovator and market leader, is pleased to announce the appointment of Barinder Rasode to its advisory board. She will be focused on assisting the Company with its advocacy to various governmental and non-governmental organizations in Canada, surrounding new regulations and updates to the current laws governing access to natural health and wellness cannabidiol (CBD) based products.

Barinder Rasode’s quintessential advocacy for Canadian values is nationally renowned. She has extensive experience working with government, industry, universities, patients, consumers, law enforcement and the private sector, finding common ground encouraging respectful, informed dialogue.

Barinder is currently the CEO of the National Institute for Cannabis Health and Education (NICHE), an independent, not-for-profit organization that provides impartial and evidence-based research about cannabis production and use in Canada. The goal of NICHE is to design and support a well-structured and holistic national strategy that considers the health and safety of Canadians as its fundamental priority.

As part of her distinguished background of accomplishments, she has served on the Board of Directors for Fraser Health, providing governance and vision for the largest health authority in British Columbia. Previously, Barinder has also served two terms as an elected Councillor for the City of Surrey, taking leadership roles in public safety and transportation.

A fierce advocate of women’s rights, Barinder is also the co-founder and Advisory Committee Chair for a unique series of conferences called “SheTalks”, featuring inspirational women who share stories of leadership, transformation, innovation, and how to succeed in today’s rapidly changing world. In addition, she is also leading the Cannabis Wisecertification program, which is set to be a recognizable and trusted way for consumers to identify products that are created with quality control, legality, and responsible use in mind.

Marcos Agramont, CEO of Isodiol, stated: “Barinder is a respected industry professional with an impeccable reputation as someone who demonstrates leadership and reinforces the importance of community building and consensus among stakeholders. We welcome her to the team and look forward to her role in representing our Company’s initiatives and discussions with the federal and provincial governments and other industry associations in Canada.”

“Isodiol is a market leader in facilitating the next phase of CBD products entering the marketplace, based on the highest quality pharmaceutical ingredients,” said Barinder Rasode. “The company works hard to be a responsible stakeholder, helping shape the future of this industry, enabling positive changes in regulations and contributing to education and awareness campaigns that are needed to empower consumers.”

Among her many accolades, Vancouver Magazine ranked Barinder Rasode as one of the 50 most powerful people in Vancouver.

About Isodiol International Inc.

Isodiol International Inc. is the market leader in pharmaceutical grade pure, natural CBD and the industry leader in the manufacturing and development of CBD consumer products.

Isodiol is the pioneer of many firsts in the CBD industry, including the commercialization of 99%+ pure, natural isolated CBD, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products. Most recently, the Company received approval for its CBD designated as an Active Pharmaceutical Ingredient for use in Finished Pharmaceutical Products, as was announced on April 26, 2018.

Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe.

Join Us On Facebook:
Twitter: @Isodiolintlinc

Marcos Agramont, CEO & Director


Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

Click here to connect with Isodiol International Inc. (CSE:ISOL) (OTCQB:ISOLD) (FSE:LB6A.F) for an Investor Presentation.


Trading resumes in:

Company: Revive Therapeutics Ltd.

Keep reading... Show less


Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE:RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), to increase the size of its previously announced offering of units (the ” Equity Units “) at a price of $0.50 per Equity Unit. Under the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, 40,000,000 Equity Units for gross proceeds to the Company of $20,000,000 (the ” Offering “). The over-allotment option granted to the Underwriters will proportionately increase to 15% of the Offering.

Keep reading... Show less

The new dispensary brings expanded access for patients in the growing communities of Central Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 77th nationwide. The new, 5,100 sq. ft. location marks the Company’s first in Summerfield expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”).

The Company announced today that its board of directors have approved a private placement of up to 15,000,000 units at a price of $.40 per unit for gross proceeds of up to $6,000,000. Each unit will consist of one common share of the Company and one share purchase warrant. Each share purchase warrant will be exercisable to purchase an additional common share at a fixed price of $.45 per share for a period of one year from closing.

Keep reading... Show less

The following issues have been halted by IIROC:

Company: Revive Therapeutics Ltd.

Keep reading... Show less